03:33 PM EDT, 05/20/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Monday the phase 3 trial of its lung disease treatment Dupixent as an add-on maintenance treatment in adults with uncontrolled chronic obstructive pulmonary disease, or COPD, met primary endpoint.

The trial showed a 34% reduction in moderate or severe COPD exacerbations over 52 weeks in patients receiving Dupixent versus placebo, the drugmakers said.

The study also achieved secondary endpoints, with more than two times greater improvement in lung function from baseline at 12 weeks and it was maintained at week 52, as well as numerically greater improvements in health-related quality of life and reductions in respiratory symptom severity from baseline at 52 weeks, the companies said.

Dupixent is currently under priority review by the US Food and Drug Administration. The target action date is June 27.

Price: 984.74, Change: +2.45, Percent Change: +0.25